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Background: The mechanism by which HIV-1 induces AIDS is still unknown. Previously, synthetic peptides
corresponding to the conserved immunosuppressive (isu) domain in gp41 of HIV-1 had been shown to inhibit
proliferation and to modulate cytokine expression of immune cells. The question is, whether the viral gp41 can do
the same.
Results: We show for the first time that two trimeric forms of glycosylated gp41 released from transfected human
cells modulated expression of cytokines and other genes in human PBMCs in the same manner, but at least seven
hundred-fold stronger compared to that induced by the isu peptide. Single amino acid substitutions in the isu
domain of gp41 introduced by site-directed mutagenesis abrogated this property. Furthermore, replication-competent
HIV-1 with a mutation in the isu domain of gp41 did not modulate the cytokine expression, while wild-type virus did.
Interestingly, most of the abrogating mutations were not reported in viral sequences derived from infected individuals,
suggesting that mutated non-immunosuppressive viruses were eliminated by immune responses. Finally, immunisation
of rats with gp41 mutated in the isu domain resulted in increased antibody responses compared with the non-mutated
gp41. These results show that non-mutated gp41 is immunosuppressive in immunisation experiments, i.e. in vivo, and
this has implications for the vaccine development.
Conclusions: These findings indicate that the isu domain of gp41 modulates cytokine expression in vitro and suppresses
antibody response in vivo and therefore may contribute to the virus induced immunodeficiency.
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The acquired immunodeficiency syndrome (AIDS) is a
complex disease characterised by a severe immunosup-
pression on the one hand and an activation of immune
cells on the other. The mechanism by which HIV-1
induces the immunodeficiency is still unclear, but it was
shown that progression to AIDS correlates with virus
load [1]. Many viruses suppress the immune system of
the infected host using different strategies. For example
herpes viruses incorporate the gene for the immunosup-
pressive IL-10 into their genome and the measles virus
uses its envelope protein for immunosuppression [2-7]. Im-
munosuppression has been described for many retroviruses,* Correspondence: dennerj@rki.de
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reproduction in any medium, provided the oramong them feline and murine leukaemia viruses (FeLV,
MuLV), and it was shown that inactivated non-infectious
retrovirus particles and purified transmembrane envelope
(TM) proteins inhibit proliferation of immune cells in vitro
(for review see [8,9]). Mangeney et al. [10,11] demonstrated
that the TM proteins of different retroviruses, including
MuLV and the human endogenous virus HERV-FRD (syn-
cytin 2, that is expressed in the human placenta), are im-
munosuppressive in vivo. All retroviral TM proteins
contain a highly conserved domain, the so-called immuno-
suppressive (isu) domain, localised in the C-terminal part
of the N-helical repeat (Figure 1). Based on the homology
of the isu sequences the retroviruses cluster into two
groups. One group is composed exclusively of lentiviruses
and the other includes beta-, gamma- and deltaretro-
viruses. Three residues (L1, Q2 and R4) are common to
both groups. Peptides corresponding to this domainal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Functional domains of gp41 of HIV-1, location and
alignment of the immunosuppressive (isu) domains of different
retroviruses. FP, fusion peptide; FPPR, fusion peptide proximal region;
NHR, N-terminal helical region; ISU, isu domain; S-S, cysteine-cysteine
loop; CHR, C-terminal helical region; MPER, membrane proximal external
region; MSD, membrane spanning domain. The location of the fusion
inhibitor T20 (Enfuvirtide, Fuzeon) is shown as a black bar. Numbering on
the top corresponds to the position according the accession number
AF324493. The alignment of the conserved sequences of the isu domain
of different retroviruses is given in the box (HIV-1, HIV-2, human
immunodeficiency virus type −1, -2; SIVcpz, simian immunodeficiency
virus of chimpanzees; HTLV-1, -2, human T-lymphotropic virus 1, 2;
MPMV, Mason-Pfizer monkey virus; SRV-1, simian retrovirus 1; MuLV,
murine leukemia virus; PERV, porcine endogenous retrovirus; syncytin
1=human endogenous retrovirus HERV-W; syncytin 2=human
endogenous retrovirus HERV-FRD; HERV-K, human endogenous
retrovirus-K). Residues common to group 1 and 2 are underlined. In
brackets proteins (p) and glycoproteins (gp) and the molecular mass in
kDa are indicated.
Morozov et al. Retrovirology 2012, 9:67 Page 2 of 15
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proliferation of peripheral blood mononuclear cells
(PBMCs) [12-16] and to modulate cytokine release, for ex-
ample, to increase IL-10 and to decrease IL-2 production
[8,17]. Based on these data it was proposed that the gp41 of
HIV-1 may play an important role in virus-induced im-
munosuppression [18]. Changes in the expression of cyto-
kines by recombinant gp41 produced in bacteria have been
reported [19-21]; however, since the protein had been pro-
duced in E. coli, contamination with bacterial endotoxin
also inducing cytokine expression cannot be ruled out.
Here we show that gp41 of HIV-1 produced in human
293 T cells (which is glycosylated and endotoxin-free)
induced considerable release of IL-10 and IL-6 by
PBMCs of healthy donors. In addition, an increase in the
expression of MMP-1 (metalloproteinase-1) and a reduc-
tion in the expression of FCN1 (ficolin 1) were observed.
The influence of ten residues in the isu domain of gp41 on
cytokine release was examined by site directed mutagenesis.Single mutations abrogated cytokine modulation. Whereas
mutations of six amino acids forming a core region in the
isu domain completely abrogated the IL-10 release, amino
acids outside the core contributed differently in a donor
dependent manner. In the case of IL-6 four of these amino
acids are crucial. The donor dependence suggests that
genetic host factors (receptor polymorphism or differences
in signal transduction?) contributed to the biological activ-
ity. In addition, gp41 with a single mutation in the core re-
gion induced a better immune response in rats immunised
with this protein compared to the wt gp41. Finally and
most important, IL-10 released from donor PBMCs was
completely abrogated when an infectious virus with a
single mutation in the core region was tested, while non-
mutated virus efficiently modulated cytokine release.
Results
Vectors encoding gp41 variants and characterisation of
the gp41 released from transfected human cells
Two expression vectors were designed, one coding for the
nearly entire wild-type (wt) gp41 with 25 residues deleted
at the C-terminus [amino acids 512–831, GenBank:
K03455] and another coding for the ectodomain of gp41
lacking the intracytoplasmic tail and the membrane span-
ning domain, gp41ΔCT [amino acids 512–695, GenBank:
K03455]. Both contained the gp120 signal peptide upstream
the gp41 sequences and were later modified in the isu do-
main by site directed mutagenesis.
Immunofluorescence analysis of 293 T cells transfected
with the vector expressing the wt gp41 revealed the pro-
tein on the cell surface and in the cytoplasm (Figure 2).
Next 293 T cells grown in FCS-free medium were trans-
fected with vectors coding for the wt gp41 and the
gp41ΔCT. The proteins were isolated from the superna-
tants and concentrated using cut-off membranes as
described (Figure 2D).
SDS-PAGE/Western blot analysis of the supernatant
from 293 T cells transfected with the vector expressing
wt gp41 revealed two glycoproteins of approximately
39 kDa and 41 kDa (Figure 2D). For simplicity the gp39/
41 proteins were called wt gp41. Deglycosylation with
PNGase F showed that these two glycoproteins have a
common protein backbone of 35 kDa, thus, they have
some differences in the glycosylation profile (Figure 2E,
left panel). The 35 kDa backbone was found also in
lysates of transfected cells (Additional file 1A). Further
evidence for glycosylation was obtained by a compara-
tive SDS-PAGE/Western blot analysis of wt gp41 and
gp41 with a mutation of the glycosylation site N637T.
The mutated N637T protein had a molecular weight of
38 kDa (Additional file 1B).
Two glycoproteins with a molecular weight of 33 kDa
and 36 kDa were found in the supernatant from cells trans-
fected with pgp41ΔCT (Figure 2D). These glycoproteins
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Figure 2 Expression of recombinant gp41 in human cells and analysis of the released proteins. (A-C) Immunofluorescence analysis of 293
cells transfected with (A) backbone vector pcDNA3.1(−) as negative control, (B) expression vector coding for wt gp41, (C) and gp41 with the
mutation Q2A in the isu domain. Proteins were detected using the mab 2F5. (D) Comparison of the wt gp41 and the mutant gp41(L1A) with
gp41ΔCT (lacking the cytoplasmatic tail) by SDS-PAGE/Western blot analysis. Proteins in the supernatant were concentrated 20 times using
30 kDa cut-off membranes. (E) Evidence for glycosylation of the gp41 and gp41ΔCT produced in 293 cells. Proteins were treated with PNGase F
(T), Nt – not treated, c – cells transfected with control vector. p35 is the non-glycosylated form of gp41 and p17 is the non-glycosylated form of
gp41ΔCT. (F) Evidence for trimerisation of the wt gp41, selected mutants and the gp41ΔCT. After transfection of 293 T cells the proteins were
concentrated 20 times as described above and a 4%-20% gradient native PAGE/Western blot analysis was performed. Positions of the trimers
(arrow heads) and the molecular markers are given (bars). (G) Expression of wt gp41 and gp41 with different mutations in the isu domain in
transfected 293 T cells grown in FCS-free medium (upper panel) and proteins recovered from FCS-free medium 48 hours post transfection and
concentrated 20 times as described (lower panel). For technical reasons, E9A was analyzed in an additional experiment. A 4-20% gradient SDS-
PAGE/Western blot analysis was performed with mab 2F5. Arrow heads indicate the position of gp41. “c” in panels D, E, F and G indicate
concentrated supernatant from cells transfected with the backbone vector.
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shown by deglycosylation with the PNGase F (Figure 2 E,
right panel), indicating a different glycosylation pattern. In
transfected cells glycosylation of the p17 occurred in
two steps, first p17 undergoes glycosylation to gp25-26
(Additional file 1C). However, this form was not released
and a part of it is likely retained in the endoplasmic
reticulum and/or in transport vesicles. The other part
undergoes further glycosylation to give rise to the 33–
36 kDa glycoproteins eventually found in the cell super-
natant (Additional file 1B, Figure 2E). Since in the cells
only traces of gp33-36 were found, they were not retained
in cellular compartments, but quickly released. The gp33-
36 glycoproteins are called gp41ΔCT.
The conformation of the released proteins was assessed
by native gradient PAGE/Western blot analysis. The wt
gp41 and gp41ΔCT formed predominantly trimers and also
some tetramers or other oligomers (Figure 2F).The effect of wild-type gp41 and gp41 with single
mutations in the isu domain on cytokine expression
To investigate the effect of wt gp41 on cytokine release,
cell supernatant containing 18 ng of the protein was
added to donor PBMCs, and after 20 hours the IL-10 re-
lease was measured by ELISA. Wt gp41 induced a re-
markably high release of IL-10 (Figure 3A, wt). The
same result was obtained when the supernatant of cells
producing gp41ΔCT was incubated with PBMCs (Add-
itional file 2), indicating that the biologically active part
is located in the ectodomain.
Next we analysed the implication of mutations of ten
individual residues in the isu domain of gp41 on cyto-
kine release. Mutations were introduced by site directed
mutagenesis into the pgp41(wt), and the mutation 2A
(Q577A) was introduced into the pgp41ΔCT. Immuno-
fluorescence analysis of cells producing gp41 with a 2A
mutation demonstrated expression of the protein in the
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Figure 3 Cytokine release from PBMCs of healthy donors in
response to exposure to the wt gp41 (black) and the mutated
gp41 (gray) as estimated by ELISA. (A) Release of IL-10 from
PBMCs of 4 donors measured in triplicates. Wt - wild-type gp41,
mock - transfection with the control vector pcDNA3(−), n.d. - not
done. PBMCs from donor 1 were tested twice within a three month
interval. (B) Comparison of medians of IL-10 release from all donor
PBMCs and determination of the P values for the influence of each
mutant on IL-10 release in comparison with the wt gp41. Error bars
represent standard deviations of sample medians, for the P values
the Student’s t test was used. 6A* - More data are required to make
a statistical analysis. (C) Schematic presentation of the influence of
mutations in the isu domain on IL-10 release, large letters indicate
abrogation of IL-10 release (core region), small letters - less
inhibition, amino acids given in gray (RYLK) were not investigated.
Numbers underlined indicate amino acid residues crucial for both, IL-10
and IL-6 release. (D) Release of IL-6 from PBMCs of donor 4 after
exposure to wt gp41 and mutated gp41s as estimated by ELISA.
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(Figure 2C). To analyse whether alanine/glycine walking
introduces conformational changes in the isu domain,
two protein structure prediction programs (DNAStarLasergene version 10, and PsiPred server, http:/bioinf.cs.
ucl.ac.uk/psipred/) were used. According to the predic-
tion the substitutions by alanine at positions L1A, Q2A,
R4A, I5A, L6A, V8A, E9A and D14A which were called
1A (L576A), 2A (Q577A), 4A (R579A), 5A (I580A), 6A
(L581A), 8A (V583A), 9A (E584A) and 14A (D589A) do
not influence the secondary structure of the isu domain.
However, substitutions of alanine by glycine (A3G, A7G)
called 3 G (A578G) and 7 G (A582G) might induce
some disturbance of the α-helical structure. Noteworthy,
mutation 14A (D589A) was introduced to compare the
effect of mutations in the isu domain of HIV-1 with that in
the isu domain (amino acid at position 14) of a murine
gammaretrovirus as well as syncytin 1 (human endogenous
retrovirus W that is also expressed in the placenta) [10,11].
Electrophoresis under native conditions demonstrated that
four mutated gp41 (mutations 1A, 2A, 8A and 14A)
released from transfected cells grown in FCS-free medium
formed trimers as was shown for the wt gp41 (Figure 2F).
To prepare proteins for the analysis of cytokine re-
lease, 293 T cells were transfected with (i) each of ten
constructs encoding gp41 with mutations, (ii) the back-
bone vector pcDNA3.1(−) (negative control) or (iii) a
construct encoding wt gp41 (positive control).
Transfected cells were grown in FCS-free medium to
allow protein concentration. An equal expression of the dif-
ferent mutants of gp41 was observed in transfected cells
(Figure 2G, upper panel). Supernatants were concentrated
twenty times and examined by Western blot analysis. Only
minor differences in the amount of released protein
(125 ng/ml to 150 ng/ml) were observed (Figure 2G, lower
panel). To analyse the influence on cytokine release, the
protein amounts were normalised and 18 ng of wt gp41
and 18 ng of each mutated gp41 were added to the PBMCs.
PBMCs of each donor were treated with a new batch of
proteins; however the stock of endotoxin-free plasmids



















































































Figure 4 Comparison of the influence of the wt gp41, gp41
with mutations (2A or 6A) and the isu peptide on cytokine
release and gene expression. (A) IL-10 release from PBMCs of
donor 4 after exposure to 18 ng/well of two gp41 mutants (Q2A
and L6A) or wt gp41 (light gray), or 12.5 μg/ml isu peptide
homopolymer (dark gray). IL-10 was measured in the supernatant by
ELISA. Mock supernatants were obtained from 293 cells transfected
with the backbone vector. (B) Activation of IL-6 and (C) MMP-1
transcription as measured by real-time RT-PCR. (D) Down regulation
of FCN1 expression as measured by real-time PCR and presented as
% of the expression induced by the isu peptide. PBMCs were from
donor 4.
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mutated in the isu domain demonstrated that the muta-
tions L1A, Q2A, A3G, R4A, E9A and D14A significantly
reduced the IL-10 release (Figure 3A). Three months
later the PBMCs from donor 1 were tested again using
the same panel of gp41 and the response was similar
(Figure 3A). Involvement of the six residues L1, Q2, A3,
R4, E9 and D14 in IL-10 release was further confirmed
using PBMCs from three other donors (2, 3 and 4,
Figure 3A). The reduction of the IL-10 release varied from
2 to 60 times and depended on the amino acid residue and
the donor of the PBMCs. The difference between the
responses to wt gp41 and gp41 with these mutations was
statistically significant (Figure 3B, Additional file 3). In con-
trast, gp41 with the mutations I5A, L6A, A7G and V8A did
not always modulate the IL-10 release. Interestingly, gp41
with the mutation V8A even increased the release of IL-10
as found in the case of the PBMCs of donor 1 (Figure 3A).
We also analysed double mutants (L1A and R4A, Q2A and
L6A). The introduction of a second mutation had no influ-
ence on the IL-10 release (not shown). Therefore, six
amino acids (L1, Q2, A3, R4, E9 and D14) were critical for
IL-10 release (Figure 3C). The mutations L1A, Q2A, A3G,
and E9A in gp41 also reduced the IL-6 expression as
shown for donor 4 (Figure 3D, Additional file 3B). Inte-
restingly, mutations R4A and D14A reduced the IL-10 re-
lease, but had little or no effect on IL-6 release, while
mutations A7G and V8A significantly modulated the ex-
pression. The reason for this discrepancy is unclear.
Thus, six amino acid residues in the isu domain of gp41
were found to be crucial for the induction of IL-10 release
(Figure 3C) and were designated as a core region. Four of
these amino acids were also crucial for IL-6 release.
Direct comparison of cytokine release from PBMCs
induced by recombinant gp41 with that induced by
homopolymers of a synthetic peptide containing the isu
domain showed that approximately 18 ng of recombin-
ant gp41 induced as much IL-10 and IL-6 as 12.5 μg of
isu peptide homopolymer as shown by ELISA and real-
time PCR (Figures 4A, B; Additional file 4). Thus, a
700–800 times lower concentration of recombinant
gp41 is required to modulate the cytokine release com-
pared to the isu peptide. The biologically active con-
formation of the isu domain in the homopolymer was
either rare and/or only partially resembling the native
conformation and therefore the homopolymers were sig-
nificantly less effective.
Using a microarray analysis, the expression of numerous
genes besides the IL-6 and IL-10 was found to be up- or
down-regulated after treatment with the isu peptide
[Denner et al., in preparation]. Among the up-regulated
genes was a gene coding for the metallopoteinase-1 (MMP-
1). MMP-1 is a member of zinc-dependent proteases that is
expressed on the surface of the monocytes andmacrophages, and it is essential for the breakdown of extra-
cellular matrix [22]. Among the down-regulated genes was
ficolin 1 (FCN1), which is involved in the regulation of the
innate immunity. FCN1 binds carbohydrates, activates the
lectin pathway of the complement system and mediates
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phagocytosis [23]. Expression of MMP-1 and FCN1 genes
was analysed in PBMCs exposed to recombinant wt gp41,
mutated gp41 (2A, 6A) and the polymers of the isu peptide
using duplex real-time PCRs (the list of primers and probes
is given in Additional file 5).
The wt gp41 suppressed the expression of FCN1 several
hundred times more efficiently compared to the isu pep-
tide. The effect of the wt gp41 on the activation of the
MMP-1 expression was also much stronger compared with
the isu peptide. In contrast, gp41 with a single mutation
(Q2A) in the core region of the isu domain was not indu-
cing MMP-1 release or reducing FCN1 expression, and
gp41 with a mutation outside the core region (L6A) did not
abrogate MMP-1 expression and did not reduce FCN1 ex-
pression (Figures 4C, D; Additional file 4).
Single mutations in gp41 of replication-competent HIV-1
completely abrogated the immunosuppressive effect
To study the immunosuppressive activity of gp41 in the
context of the viral particle, mutations (Q2A and Q2A+
L6A) were introduced into gp41 in the infectious molecu-
lar clone HIV-1 pNL4-3 (Figure 5A). 293 Tcells were trans-
fected with the wt and mutated HIV-1 pNL4-3 and 48 h
later the viruses were isolated from the cell supernatants by
centrifugation through a 20% sucrose cushion.
No differences in the protein pattern (including gp41)
of wild-type and mutated viruses were observed by
Western blot analysis (Figure 5B, C). Mutated viruses
were infectious as shown by an infectivity assay per-
formed on TZM-bl cells and the titres of the mutated
and wt viruses were of the same magnitude (Figure 5D).
However, for our experiment it was essential to have the
same amount of gp41 in each virus preparation. The
concentration of gp41 in the preparations was assessed
by Western blot analysis using as reference serial dilu-
tions of the T20 peptide and the mab 2F5 (Figure 5E).
To avoid a possible activation of cytokine genes by pro-
virus insertion, the viruses were inactivated by 6 times
freeze-thawing. 1.25 ng of viral gp41 with and without
mutations in the isu domain were used to induce IL-10
release from 1x105 PBMCs from donor 1. The amount
of IL-10 induced by the mutated viruses was approxi-
mately 700 fold lower (close to lowest detection limit)
compared with that induced by the wt virus (Figure 5F).
Comparative analysis of the isu peptide, wt gp41 and
gp41 in the virus particles indicated that gp41 in the
virus was nearly 1 × 104 times more efficient in induction
of IL-10 release compared to the isu peptide and 15
times more efficient than wt gp41 alone. These data in-
dicate that the conformation of the isu domain and pos-
sibly the microenvironment of the viral envelope may be
important in promoting cytokine modulation. Given the
fact that a single amino acid substitution in gp41 inhibitsthe entire immunosuppressive activity induced by the wt
virus, other molecules present in the virus preparation
were not involved in cytokine modulation.
Mutations in the isu domain led to higher antibody
responses
Comparison of the immune response against wt gp41
and gp41 with a single mutation (Q2A) in the core re-
gion was an approach to analyse gp41-induced immuno-
suppression in vivo. Noteworthy, gp41 is the target of
broadly neutralising antibodies such as 2F5 and 4E10
isolated from HIV-1 infected individuals [24] and an im-
portant antigen for vaccine development. In this regard,
the implication of the isu domain of gp41 on the im-
mune response was also important to examine.
Two rats were immunised subcutaneously with 200 ng
of wt gp41 and two rats with mutated gp41(Q2A) fol-
lowed by three boosts with the same amount of the anti-
gens. An increased antibody response was observed
when the mutated gp41 was used for immunisation
compared with the wt gp41 (Figure 6A). In a second ex-
periment gp41ΔCT was used for immunisation. This
protein demonstrated the same rate of cytokine release
when tested in vitro to the entire wt gp41 (Additional
file 2). Three rats were immunised with 250 ng of
gp41ΔCT and three rats were immunised with 250 ng of
mutated gp41ΔCT(2QA) (Figure 6B, C). The immune
response to the wt gp41ΔCT was weak, whereas the re-
sponse to the mutated gp41ΔCT was much stronger as
shown by ELISA against the T20 peptide and Western
blot analysis using the recombinant ectodomain of gp41
produced in bacteria. These data confirmed and
extended the results of the first experiment (Figure 6A).
Mutations abrogating the immunosuppressive effect were
not found in proviruses from HIV-1 infected individuals
Interestingly, the analysis of the isu domain polymorphisms
using the Los Alamos HIV and the GenBank databases
(more than 2000 HIV-1 sequences were examined) did
not reveal mutations of the type L1A, Q2A, A3G, R4A,
L6A, A7G, E9A and D14A in the isu domain of HIV-1
sequences from infected humans (the analysis of 250
sequences is shown in Table 1), indicating that these
amino acids are crucial for the viral life cycle.
Further analysis of the sequences from data banks
showed that the residues L1, R4, E9 and L12 (not exam-
ined) are the most conserved. This observation largely sup-
ports our data demonstrating critical residues in the isu
domain (Figure 3C). Notable, the residues L1, Q2 and R4
are identical in the isu domain of all retroviruses (Figure 1).
The mutation V8A that enhances the IL-10 release from
PBMCs of donor 1 compared with the wild-type gp41
(Figure 3A) was found in viral sequences from infected
individuals (Table 1). Using the BLOSUM62 amino acid
Figure 5 Replication-competent HIV-1 with mutation in the isu domain does not induce IL-10 release. (A) Mutations introduced to the isu
domain of gp41 HIV-1. The upper numbers started from the first amino acid in Env (accession number AF324493), the lower numbers - with the
first amino acid in gp41. The mutated amino acids are underlined. (B) Comparison of the virus-specific proteins in transfected cells and (C) in the
virus centrifuged through a 20% sucrose cushion. 1 - wild-type HIV-1pNL4-3; 2 - mutated HIV-1pNL4-3 (Q2A); 3 - double mutated HIV-1pNL4-3
(Q2A+ L6A); 4 - negative control, cells transfected with pcDNA3.1(−). A 4-20% gradient SDS-PAGE/Western blot analysis was performed with the
mab 2F5 (B, C lower panel) and with pooled sera from HIV-1 infected individuals (C, upper panel). (D) Infectious titers of wt (pNL4-3) and
mutated viruses HIV-1pNL4-3 (Q2A) and HIV-1pNL4-3 (Q2A+ L6A) determined on the reporter TZM-bl cell line. Analysis was performed in triplicates.
Mock – supernatant from cells transfected with pcDNA 3.1(−). (E) Estimation of the amount of gp41 in virus preparations by SDS-PAGE/Western
blot using serial dilutions of T20 as reference. 1–50 ng/lane; 2–25 ng/lane; 3–12.5 ng/lane. Purified HIV-1pNL4-3 was analyzed in two dilutions
equivalent to 4 × 105 (Track 4) and 2 × 106 (Track 5) infectious particles per lane. Western blot was performed using the mab 2F5. (F) IL-10 release
from PBMCs of donor 1 that were exposed to the wt and mutated viruses inactivated by freeze-thawing. Viruses were diluted twofold; the initial
concentration of gp41 was 5 ng/well. The p values were determined as described in Methods.
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such as Q2R and V8L/I/M described in gp41 from infected
individuals were homologous. The evaluation of the disease
progression and the cytokine profile in individuals with
V8A substitutions in the isu domain might be important
for a better understanding of the putative mechanisms of
immunosuppression induced by HIV-1 in vivo.
Discussion
Understanding the HIV-1 induced pathogenesis remains
a fundamental problem in AIDS research and antiviral
therapy. Two principal mechanisms are considered to be
involved; first, direct or indirect killing of immune cells
and second a general dysregulation of these cells. Based
on in vitro and in vivo experiments we provide evidencethat the TM protein gp41 of HIV-1 may be involved
in dysregulation of the immune cells, partially by the
modulation of the expression of cytokines associated with
immunosuppression.
For the first time glycosylated wt and mutated gp41 were
produced in human cells. The proteins were recovered
from the cell supernatant, characterised and analysed for
their immunosuppressive properties. Furthermore, two in-
fectious and replication competent variants of HIV-1 with
mutations in the isu domain of gp41 were obtained and
examined for their influence on cytokine expression. The
systematic and comparative analyses of the properties of
the isu domain of gp41 of HIV-1 included (i) glycosylated
gp41 released from transfected human cells, (ii) gp41 in
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Figure 6 Enhanced immune response after immunisation with gp41 mutated in the isu domain. (A) Comparative ELISA of sera from two
rats immunised with the wt gp41 and with the mutated gp41(Q2A). T20 (100 ng per well) was used as antigen. (B) Comparative ELISA of sera
from rats immunised with the mutated gp41ΔCT(Q2A) (rats 1–3) and rats immunised with the wt gp41ΔCt (rats 4–6), all without the
cytoplasmatic tail and the membrane spanning domain. 100 ng of T20 per well were used as antigen. Sera were diluted 1–1:200. 2–1:400,
3–1:800, 4–1:1600. (C) Western blot analysis of the rat sera using the recombinant ectodomain of gp41 (17 kDa) produced in bacteria. Lane 1,
2 - pre immune sera from rats 1 and 6, lane 3 - mab 2F5 (positive control), lanes 4–6 - sera from rats 1, 2 and 3, all immunized with mutated
gp41ΔCt (Q2A), lanes 7–8 - sera from rats 5 and 6, both immunized with wt rgp41ΔCT. The rat sera were diluted 1:200, the mab 2F5 was used at
2 μg/ml, rabbit anti-rat and rabbit anti-human sera conjugated with alkaline phosphatase at 1:2000.
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and the isu peptide in microgram amounts) induced a sig-
nificant increase in IL-10 and IL-6 expression. KeyTable 1 Frequency of mutations in the isu domain in provirus
# aa A D E G F L S Y C W
1 L 0 - - - 0 * 0 - - 0
2 Q 0 - 0 - - 0 - - - -
3 A * 0 1 0 - - 1 - - -
4 R 0 0 - 7 - 0 0 - 0 0
5 I 1 4 - 0 1 5 0 - - -
6 L 0 - - - 0 * 0 - - 0
7 A * 1 1 0 - - 3 - - -
8 V 3 0 0 2 0 69 - - - -
9 E 0 1 * 4 - - - - - -
10 R 4 - - 22 - 0 9 - 0 0
11 Y 0 0 - - 13 - 0 * 9 -
12 L 0 - - - 0 * 0 - - 0
13 K 27 - 72 97 - - 15 6 1 41
14 D 0 * 1 6 - - - 3 - -
250 HIV-1 sequences most closely related to the isu domain with the consensus seq
Numbers indicate the frequency of a substitution at a given position. “-“ indicates t
acid, “0” indicates absence of corresponding mutations among the 250 analyzed se
given in bold. Please note that no mutations 1LA, 1QA, 4RA, 6LA, 9EA and 14DA asresidues in the isu domain required for the biological
(immunosuppressive) activity were identified. Based on
this data we speculate that the putative binding site of thees from infected patients
V P H Q R I M T N K
0 1 0 0 2 0 0 - - -
- 9 2 * 94 - - - - 3
1 0 - - - - - >100 - -
- 0 0 0 * 0 0 1 - 1
>100 - - - 0 * 0 0 0 0
1 3 0 4 2 0 0 - - -
1 0 - - - - - 35 - -
* - - - - 92 79 - - -
0 - - 0 - - - - - 5
- 0 0 1 * 0 0 18 - 22
- - 3 - - - - - 0 -
0 3 0 0 0 1 0 - - -
3 - 41 >100 >100 0 13 37 2 *
1 - 15 - - - - - 1 -
uence shown in Figure 1 were analyzed for mutations in each position.
hat more than one nucleotide substitution is required to change the amino
quences, * indicates substituted residues. The most conserved residues are
well as no 3AG and 7AG were found.
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discontinuous (the first 4 amino acids as the first part and
position 9 to 14 as the second part). It was shown that im-
munisation with gp41 mutated in the isu domain resulted
in a higher antibody response. Finally, we demonstrated
that a single mutation (Q2A) in the isu domain of gp41 of
replication-competent HIV-1 completely abrogated the
immunosuppressive effect. All together these results indi-
cate that the isu domain is the biologically active domain
of gp41 of HIV-1 and the protein may directly interfere
with the immune system. These results also shed light on
the mechanism of HIV-1 pathogenesis and should be con-
sidered when designing gp41-directed vaccines.
An increase in IL-10 and IL-6 release from PBMCs as
observed in our experiments was found in the blood of
HIV-1 infected individuals [25-29]. Although considered
as an immunosuppressive molecule, IL-10 has pleio-
tropic properties and modulates the function of several
adaptive immunity-related cells and has a stimulatory ef-
fect on B cells [4]. Noteworthy, a modulation of cytokine
release was also shown in vitro for the recombinant TM
proteins and the isu peptide of gammaretroviruses
[17,30] as well as for the human endogenous retrovirus
HERV-K (unpublished). Thus, the immunosuppressive
effect of the TM proteins seems to be a common prop-
erty of retroviruses. In this regard it would be of interest
to compare the immunosuppressive potential of the TM
protein of other retroviruses with that of the gp41 of
HIV-1 and the gp36 of HIV-2.
The mechanism of the cytokine modulation induced
by gp41 of HIV-1 remains largely unknown. Although
several laboratories reported binding of gp41 to the cell
surface [31-34], it remains unclear whether there is a re-
ceptor(s); and if there is a receptor, how gp41 triggers
signal transduction. The following mechanisms may be
proposed: (i) The isu domain may interact specifically
with a receptor(s) on the cell surface triggering release
of cytokines and other factors, which then induce add-
itional changes in gene expression and cytokine release.
(ii) The isu domain of gp41 may bind non-specifically to
different receptors, e.g., single-spanning transmembrane
receptors, for example Toll-like receptors (TLR), inducing
dimerization and triggering expression of numerous cyto-
kines, or (iii) it can be a reverse agonist for the receptor(s).
In fact, the observed differences in the modulation of cyto-
kine expression in donor 4 (mutations in position L4 and
D14 abrogated IL-10 release, but not IL-6 release)
may be explained by some differences in the ligand
binding site of the receptor(s). In addition a sequence
homology between domains in the type I interferons
(IFN) and the isu domain of gammaretroviruses and
HIV-1 was reported [8,35], and all type I IFNs al-
though different in their sequence bind to a common
receptor [36].Recently a highly conserved region (SWSNKS) in the
C-terminal helical region of gp41 was described, which
binds to a specific receptor, the globular complement 1q
receptor (gC1qR), and induces an increased expression
of NKp44L, a cellular ligand for an activating NK recep-
tor on CD4+ cells. This may be one reason for the elim-
ination of CD4+ cells by NK cells and indicates another
mechanism of immunosuppression induced directly by
the gp41 protein [37].
The question whether the amount of gp41 in an
infected individual is high enough to induce immuno-
suppression in vivo is related to the question where gp41
can be found in the organism. The gp41 with an access-
ible isu domain may be found on the surface of virus
particles after shedding of gp120, in immune complexes,
and in debris from dead cells, but the main amount will
be found on the surface of infected and virus producing
cells in the blood and in lymphoid organs.
Apparently the amount of gp41 in the body of an
infected individual is impossible to calculate. Based on
our in vitro data we attempted to estimate the possible
amount of gp41 in the blood of an infected individual.
The amount of gp41 in the HIV-1pNL4-3 virus preparations
was quantified by SDS-PAGE/Western blot analysis using
serial dilutions of T20 as a reference (Figure 5E). In our ex-
periment 12.5 ng of gp41 were found in a preparation con-
taining 1x106 infectious virus particles. Thus, one infectious
particle was “associated” with 12.5 fg of gp41 (coefficient of
association). It is important to underline that in addition to
gp41 present in the infectious particles, the preparation
contained gp41 from a large number of non-infectious par-
ticles. Based on the coefficient of association the following
equation was developed:
X ¼ C 10nð Þ  V
where X is the amount of gp41 in the blood; C is the coeffi-
cient of association; 10n is the infectious titre/ml; and V is
the volume of the blood in ml. For example, if the infec-
tious titre in an infected individual is 1×104/ml, then
5×107 infectious virus particles associated with 0.625 μg
(0.9× 1013 molecules) of gp41 are present in the blood. Also
assuming that 1×1010 lymphocytes are circulating in the
blood, then 9×102 molecules of gp41 may interfere with
one cell. In our in vitro experiments (i) 2× 106 molecules of
wt gp41 produced in human cells, and (ii) 1× 105 molecules
of virus associated gp41 per cell were able to induce
changes in the cytokine release. Therefore, the amount of
wt gp41 per cell that was used in vitro was nearly 2000
times higher and the amount of wt gp41 per cell that was
about 100 times higher compared to estimated amount of
virus-associated gp41 in the blood of an individual with an
infectious titre of 1× 104/ml. This calculation did not take
into account the substantial amount of gp41 on the surface
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counting only the virus-associated gp41, an immunosup-
pressive effect in the blood of the patient comparable to
that seen in vitro could be achieved if the infectious titre is
above 1×106/ml.
However, the lymphoid organs have been proposed as
the major reservoir of HIV-1 [38]. Numerous molecules
of gp41 expressed on the membranes of infected cells in
lymphoid organs can actively interact with neighbouring
uninfected cells and modulate the cytokine release in a
long lasting manner. Thus, taking this point into consid-
eration, the gp41 induced immunosuppression might be
significant when the load of infectious virus is much
lower than 1 × 106/ml. Since the conformation of gp41
on the cell surface and on virus particles might be differ-
ent (full size functional gp41-gp120, and thermodynam-
ically stable gp41 stumps, both as trimers or monomers
[39]), it still remains to be determined which conform-
ation modulates cytokine release best.
The viruses with mutations in the isu domain were in-
fectious (Figure 5D), and therefore the mutation did not
abolish virus replication. In this regard, the fact that cer-
tain mutations such as Q2A in the isu domain abrogating
the cytokine modulating activity were not found in HIV
sequences from infected individuals indicates that non-
immunosuppressive viruses might be present only as
minor quasispecies and could not represent a majority;
otherwise they would be cleared by the immune system.
Recently, using a classical laboratory model, a murine
retrovirus (MuLV), it was shown that mutations in the isu
domain abrogated its ability to suppress the innate and
adaptive immune response (NK and CD8+ cells) of the im-
munocompetent host [40]. This mutation also did not in-
fluence the replication capacity.
There are still open questions. For example, the virus
load in African green monkeys infected with the simian
immunodeficiency virus (SIVagm) and in sooty manga-
beys infected with SIVsm is as high as in HIV-1-infected
individuals [41]. Despite the presence of an isu domain
in their TM protein, these SIV do not induce AIDS in
their natural host. However, a trans-species transmission
of SIVsm to rhesus monkeys resulted in AIDS in the
new host, suggesting that the isu domain is functional
and that the natural host adapted to it, either by lack of
or structural changes in the putative receptor or by dis-
ruption of the signal transduction pathway.
Our studies showed that immunisation with gp41 with
point mutations in the isu domain induced a better im-
mune response in 4 of 5 rats compared to immunisation
with the wt gp41 (Figure 6). It may be possible that con-
formational changes in the mutated isu domain promote
a better immune response, but this was not supported by
protein conformation prediction analysis. Similar improved
immune responses were reported in mice immunised withthe TM protein of the Friend-MuLV mutated in the isu
domain in comparison with the wild-type protein; or with
the recombinant human syncytin 1 (not immunosuppres-
sive) in comparison with syncytin 2 (immunosuppressive)
[10,11].
Viruses developed numerous, often multiple mechan-
isms allowing suppression of the innate and adaptive im-
munity [3-7,42]. HIV-1 is not an exception and exploits
several strategies to overcome immune responses, for
example, down-regulating CD4 and MHC-1 by Nef [43].
In addition, infection of cells by HIV-1 endocytosis may
be regarded as a strategy to minimise the contact of the
virus with the immune system [44]. Both Tat and gp120
contribute to the deregulation of the immune system,
and therefore may be involved in immunosuppression
leading to AIDS [45,46]. In this context, it is of interest
that the surface envelope protein gp105 of HIV-2
induced a stronger inhibition of T cell proliferation than
HIV-1 gp120, in spite of the lower HIV-2 pathogenicity
in vivo, indicating that gp120 is not the key molecule in
inducing immunosuppression [47]. In in vitro studies it
was shown that gp120 from HIV-1JR-FL and HIVLAI
induced IL-10 expression in human monocyte-derived
dendritic cells via a mannose C-type lectin receptor, but
gp120 from HIVKNH1144 did not [48]. Since gp41 is gly-
cosylated, it may interact with such receptors; however
the results with the isu peptide homopolymer and the
mutations in the isu domain which do not alter glycosy-
lation indicate that glycosylation of gp41 is not involved
in cytokine modulation.
It is important to underline that gp41 and gp120 are
the first viral proteins that interfere with the immune
system during the initial step of infection. Nef and Tat
are produced only after infection, and may contribute to
the immunosuppression later. In addition, the envelope
proteins (especially gp41 anchored in the cell mem-
brane) are expressed on the surface of infected cells and
may permanently interact with the immune system.
Conclusions
In conclusion, gp41 induced a remarkable modulation of
cytokine expression in human PBMC. However, recom-
binant gp41 and HIV-1 particles with single mutations
in the isu domain failed to induce cytokine release. Six
mutations in the isu domain impaired the cytokine
modulation stronger than others. Recombinant gp41 was
shown to suppress the antibody response in immunised
animals. The gp41-induced cytokine deregulation may
contribute to the suppression of the innate and adaptive
immunity in HIV-1 infected individuals and may pro-
mote virus replication and decrease protection from op-
portunistic infections. In the course of infection the
immunosuppressive effect is likely increasing as a conse-
quence of the increase in virus/gp41 load in the blood and
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Tat and Nef with the immune system and an activation of
immune cells due to a strong immune response against
HIV-1 and other infectious microorganisms take place.
All these processes overlap resulting eventually in the clin-
ical picture of AIDS.
Methods
Cells
293 T (HEK 293 T) cells were obtained from ATCC
(CRL11268), and the reporter TZM-bl cell line was
obtained through the NIH AIDS Research & Reference Re-
agent Program (Cat. # 8129) as contributed by Drs John
Kappes and Xiaoyun Wu. The cells were maintained in
DMEM supplemented with 10% heat-inactivated fetal calf
serum (FCS), antibiotics and L-glutamine.
Sera and monoclonal antibodies
Pooled human sera from HIV-1 infected individuals (HIV
Blot 2.2 kit, MP Diagnostics, Singapore) and 2F5, a human
monoclonal antibody against gp41 (recognizing the epitope
ELDKWA), kindly provided by Dr. H. Katinger (Polymun,
Vienna, Austria), were used.
Design of expression vectors, site-directed mutagenesis
and plasmid purification
The pNL4-3 molecular clone [catalog # 114, GenBank:
AF324493] was obtained from the NIH AIDS Research
& Reference Reagent Program. The gp41 PCR amplicon
was obtained from pNL4-3 by PCR amplification using
primers with introduced XhoI and XbaI restriction sites
(underlined): forward primer starting with position 7725
(XhoI) 5’- gagtggtgcagagagaaactcgagcagtggg and reverse
primer starting with 8722 (XbaI) 5’- agctgcttgttatacttcta
gaaccctat. The amplicon was treated with XhoI and XbaI
endonucleases (Fermentas Life Sciences, Germany) and
ligated into the pcDNA3.1(−) (Invitrogen Life Technolo-
gies, Carlsbad, CA, USA) together with the gp120 signal
peptide using T4 DNA ligase (Fermentas). The signal
peptide was introduced as a synthetic sequence with
NheI and XhoI restriction sites (5’ctagcatgagagtgaaggaga
agtatcagcacttgtggagatgggggtggaaatggggcaccatgctccttggg
atattgctcgag3’) and ligated to the pcDNA3.1(−) previously
cleaved with NheI and XhoI. The vector (p wt gp41)
expressed the gp41 with a 25 amino acid deletion at the
cytoplasmatic tail (designated wt gp41). Truncated gp41,
designated gp41ΔCT, lacking the cytoplasmic tail and the
membrane spanning domain (amino acids 512–695)
[GenBank:NC001802], was expressed from the pgp41ΔCT
vector designed in the following way: HIV-1pNL4-3 was
amplified by PCR with primers containing the XhoI and
XbaI restriction sites (underlined): foreword primer start-
ing with position 7725 (XhoI) 5’- gagtggtgcagagagaaactcg
agcagtggg and reverse primer starting with 8264 (XbaI)5’- ttttatctagaacagccaatttg. The amplicon was digested
with XhoI and XbaI endonucleases (Fermentas) and
ligated into the pcDNA3.1(−) (Invitrogen) together with
the gp120 signal peptide using T4 DNA ligase (Fermentas)
as described above.
Site-directed mutagenesis was performed using the
QuickChange multisite-directed mutagenesis kit (Strata-
gene, La Jolla, CA, USA) according to the protocol of the
manufacturer. Eight amino acids in the isu-domain were
substituted by Ala and Ala at positions 3 and 7 were sub-
stituted by Gly; two double mutations L1A+R4A and
Q2A+L6A were also introduced to the cloned gp41.
Using the vector expressing wt gp41 mutations were
introduced to the glycosylation site N637T as described
above.
To introduce the substitutions to the pNL4-3, the env
fragment between nucleotides 7489 and 8526 was amplified
by PCR using the primers: forward 5’-catgtggcaggaagtagg-3’
(position7489-7506) and reverse 5’-aagcggtggtagctgaag-3´
(position 8509–8526) and cloned in pTARGET (Promega,
Madison, WI, USA). Site-directed mutagenesis was per-
formed as described above. Plasmids with substitutions in
the isu-domain were cleaved with Bam H1-Bse J1 and
ligated using T4 DNA ligase (Promega) to pNL4-3 previ-
ously cleaved with Bam H1-Bse J1 (Fermentas). After
ligation and transformation plasmids were isolated using a
Wizard Plus SV Miniprep Kit (Promega) and Pure Yield
Plasmid Midiprep System (Promega) and verified by restric-
tion analysis and sequencing. In order to reduce the endo-
toxin level below 0.3 EI/ml, plasmids were purified twice
using the MiraClean Endotoxin Removal kit (Mirus Bio,
Madison, WI, USA). Low level of bacterial endotoxin in
plasmids was confirmed by the LAL QCL-1000 test (Lonza,
Verviers, Belgium).
Transfection of cells, recovery of proteins from cell
supernatants, and deglycosylation
293 T cells were washed three times with DMEM followed
by culturing the cells in FCS-free medium containing as
supplement 10% of Liforcell (Lifeblood media supplement,
USA) to eliminate FCS proteins and allowed later concen-
tration of gp41. 5-6×105 cells were transfected with 3 μg of
plasmid using 12 μl of TransIT-293 transfection reagent
(Mirus Bio). 48 hrs post transfection the supernatants were
harvested and centrifuged at 3000 g for 10 minutes and at
10000 g for 10 minutes. The supernatants were filtered
through a 0.22 μm filter (Millipore GmbH, Germany) and
concentrated 20–40 times using Vivaspin 4 concentrators
(Sartorius Stedim Biotech GmbH, Göttingen, Germany)
or U-tube concentrators (Novagen, EMD, Darmstadt
Germany). The amounts of gp41 in cell supernatants
were measured by Western blot analysis using as a
reference serial dilution of T20 and the mab 2F5 for de-
tection. To analyse glycosylation of the proteins, they
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of the supplier (New England Biolabs, Inc., Ipswich, MA
USA) and examined by SDS-PAGE/Western blot.
Immunofluorescence
293 T cells were seeded on poly-L-lysine coated glass
slides one day before transfection and transfected as
described above. 48 hours post-transfection cells were
washed with PBS and fixed for 10 minutes with 2.5%
paraformaldehyde. Then the cells were washed twice
with phosphate-buffered saline (PBS), permeabilised with
0.5% Triton X-100 (10 minutes), washed three times with
PBS, blocked for 45 min with blocking buffer (1x PBS, 1%
glycine, 0.1% Triton X-100) at room temperature and incu-
bated with the mab 2F5 (20 μg/ml) in blocking buffer for 1
hour at room temperature. Cells were washed 3 times in
PBS with 0.1% Triton X-100, stained with secondary anti-
human Alexa Fluor 488 conjugate (Invitrogen), diluted
1:200 in blocking buffer and incubated for 1 hour at room
temperature in the dark. The cells were washed 3 times
with PBS and 0.1% Triton X-100, 3 times with PBS and
analysed using an LSM 510 (Carl Zeiss, Oberkochen,
Germany) confocal microscope using the LSM 5 Image
Examiner software (Carl Zeiss).
SDS-PAGE, native PAGE and Western blot analysis
Electrophoresis was performed in Tris-Glycine 4%–20%
gradient gels using SDS Tris-Glycine sample buffer
(Novex, Life technologies, Carlsbad, CA, USA). Native
PAGE was performed in 4-20% Tris-Glycine gels using
Tris-Glycine native running buffer (Novex) and samples
in SDS free loading buffer were not heated before run.
Proteins were transferred onto Protran BA83 0.2 μm
membrane (Whatman GmbH, Dassel, Germany) at 45 V
for 2 hours. Membranes were blocked with 6% skimmed
milk in PBS with 0.1% Tween 20 (block buffer) for
3 hours at room temperature or overnight at 4°C, incu-
bated for 2 hours at room temperature with serum from
HIV-1 infected individuals or anti-gp41 mab 2F5 diluted
in blocking buffer (1 μg/ml). After five times (5 min
each) washing in PBS with 0.1% Tween 20 (PBS-Tween)
the membranes were incubated for 1 hr with anti-human
IgG-HRP conjugate (Dako Laboratories, Glostrup,
Denmark) diluted 1:10000 in blocking buffer. The mem-
branes were washed five times (5 minutes each) in PBS-
Tween, treated for 1 minute with Pierce ECL Western
blotting substrate (Pierce, Rockford, IL, USA) and exposed
to CL-XPosure film (Thermo Scientific, Rockford, IL,
USA). To detect antibodies against gp41 the recombinant
ectodomain of gp41 produced in E. coli was used as
antigen.
Peptides and peptide polymers
Synthetic peptides corresponding to the immunosuppres-
sive domain of gp41 of HIV-1 (aa 574–592 [GenBank:K03455]), (KQLQARILAVERYLKDQQL) (Figure 1)
were produced by Genaxxon BioScience GmbH, (Ulm,
Germany) or JPT, Jerini, (Berlin, Germany). Homopoly-
mers of the peptides were produced by cross-linking
with EDC and NHS (Pierce) as recommended by the
supplier. T-20 (Fuzeon, aa 638–673, GeneBank: K03455,
YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,
Roche, Mannheim, Germany) was used as reference for
the estimation of the gp41 amount in cell supernatants,
virus particles and as antigen in ELISA.
Human PBMCs
PBMCs were isolated from the blood of healthy donors
by Ficoll-Hypaque (PAA Laboratories, Linz, Austria)
density centrifugation using Leucosep tubes (Greiner
Bio-one GmbH, Frickenhausen, Germany). Cells were
washed and dissolved in complete RPMI 1640 medium
containing 10% FCS, (Biochrome AG, Berlin, Germany)
L-glutamine and antibiotics. A batch of FCS was selected
which does induce only very low amount of IL-10. 1x105 of
PBMCs in 100 μl were mixed with 50 μl of gp41 protein
(18 ng), peptide (12.5 μl) or virus (1.25 ng) and with 50 μl
of complete RPMI medium. The cells were incubated at
37°C for 20-24 hours and cytokine release was measured
by ELISA.
ELISA for IL-6 and IL-10
Supernatants from PMBCs (1×105 cells/well) either un-
treated or treated for 24 hours with the peptide polymers,
gp41 or inactivated HIV-1 were collected, centrifuged at
2000 g for 10 min and tested by ELISA. The ELISAs were
performed in triplicates according to the protocols of the
suppliers of the IL-6 and IL-10 kits (BD Biosciences, San
Diego, CA, USA). T20 ELISA was performed in 96 wells
with 100 ng of the peptide per well.
RNA isolation from PBMCs
RNA was isolated from donor PBMCs exposed to the
supernatants containing wt gp41 or mutated gp41. In
total, 1.8 × 106 cells were used for RNA isolation using
the RNeasy kit (Qiagen, Hilden, Germany). The RNA
concentration was measured using a NanoDrop spec-
trometer ND-100 (PEQLAB Biotechnologie GmbH,
Erlangen, Germany), and RNA specimens were used im-
mediately in RT-PCR or kept at −80°C before use.
One-step real-time quantitative PCR
One-step real-time RT-PCRs were established for human
IL-6, IL-10, MMP-1 and FCN-1 (Additional file 4), and
duplex PCRs were performed using GAPDH for normal-
isation (ΔCt =Ct gene of interest – Ct GAPDH). Total
RNA was isolated as described above. Primers and
probes for PCR were selected using the Sigma Genosys
Probe Design Program and obtained from this company.
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PCR was performed in triplicates in 25 μl (total volume)
using 0.5 μl of polymerase from Super Script III Platinum
one-step qRT-PCR kit (Invitrogen).
The thermal cycling profile for IL-10 was the following:
50°C/10 minutes and (95°C/15 s-56°C/30s-72°C/30s) 40
cycles, hold at 4°C. The thermal cycling profile for IL-6,
FCN 1 and MMP-1 was the following: 50°C/10 minutes
and (95°C/15 s-60°C/1 min) 45 cycles, hold at 4°C.
Reporter fluorescence was measured using an Mx4000
Multiplex Quantitative PCR System (Stratagene, La
Jolla, CA, USA) and evaluated using the 2-ΔΔCT
method [49].
Virus preparations
Briefly, 293 T cells (1 × 106) were transfected with 3 μg
of each - pNL4-3, pNL4-3(A2) and pNL4-3(A2+A6)
using 4 μl/μg of Mirus TransIT-293 transfection reagent
as described above. 48 hrs post transfection the superna-
tants were harvested, centrifuged at 3000 g for 10 min
and at 10,000 g for 10 minutes. Supernatants were fil-
tered through 0.45 μm filter (Millipore), centrifuged
through a 20% sucrose cushion at 32000 rpm (rotor SW
50.1Ti, Beckman, Ireland) for 3 hours. Viruses were col-
lected in PBS and used immediately or stored at -80°C
until use. Virus preparations were added to PBMCs after
six cycles of freeze-thawing procedure.Virus titration in TZM-bl cells
Infectivity was estimated in TZM-bl cells using 96-well
plates and supernatants from two independent transfec-
tion experiments. 4 × 103 cells per well were plated and
incubated overnight at 37°C. On the next day when the
cell monolayer was about 40-50% confluent, the medium
was removed. 10 μl of virus-containing supernatants
from transfected cells were diluted in 90 μl of complete
medium and added to the TZM-bl cells. Titration was
performed in triplicates by serial tenfold dilution. After
24 hours the medium was replaced; and 24 hours later,
cells were washed twice with PBS and fixed with 2% par-
aformaldehyde for 5 minutes. Cells were washed twice
with PBS and stained with X-gal (0.5 mg/ml) in PBS
containing 5 mM K-ferric cyanide and 5 mM K-ferro
cyanide and 2 mM MgCl2. Cells were incubated at room
temperature in the dark, and on the next day blue-
stained (β-Gal+) cells were counted using light micro-
scope. Groups of blue-stained cells were counted as sin-
gle foci of infection and wells containing >5 blue-stained
cells were used for calculation.
Immunisation studies
Wild-type gp41 and gp41 with the mutation Q2A in the
isu domain both with and without the cytoplasmatic tailwere produced by transfected 293 T cells and proteins
were isolated from the supernatants of cells and concen-
trated as described above. Four rats were immunised
subcutaneously with wt gp41 and mutated gp41 (200 ng
per animal/per immunisation/boost), using complete
(for immunisation) and incomplete (for boost immunisa-
tion) Freund´s adjuvants. Sera were taken after the sec-
ond boost and analysed in an ELISA (dilution 1:200) for
antibodies binding to T20 and in a Western blot analysis
with the ectodomain of gp41. Three rats were immu-
nised with gp41ΔCT and three rats with mutated
gp41ΔCT (Q2A) in the same way as described above. In
these experiments 250 ng of antigen per animal/immun-
isation or boost were used. The animals were immunised
according the German Animal Protection Law. The
Landesamt für Gesundheit und Soziales Berlin reviewed
and approved the protocol of the animal study (Approval
number H0201/02).
DNA analysis, protein structure analysis and protein
calculation
The programs DNAStar Lasergene version 10, Clone
Manager Professional version 10 and PsiPred server
(http:/bioinf.cs.ucl.ac.uk/psipred/) were used for ana-
lysis of the nucleotide sequences and predictions of
protein conformation. The calculation of gp41 in
virus particles was based on our measurements per-
formed by Western blot analysis with serial dilutions
of reference peptide (T20). Estimation of the gp41 in
association with virus particles was based on the
known infectious titre and the estimated amount of
gp41 using reference peptide (T20); and the infec-
tious titre of the virus and also on published data
[50].Statistical analysis
Medians for each triplicate donor PBMCs cytokine
responses to gp41 (wt and mutants) were calculated,
and their statistical significance was assessed using
Student’s t test. P values of samples were calculated
versus the wt gp41. Then, medians of the released
IL-10 from each donor PBMCs were taken as basis
data, and new medians encompassing all donors
PBMCs responding to a particular protein were esti-
mated. P values of these medians were calculated
versus the wt median.Ethical statement
The use of human blood has been approved by the ethical
commission at the Medical Faculty of the Humboldt Uni-
versity Berlin. Written informed consent was provided by
study participants.
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Additional file 1: Detection of non-glycosylated and glycosylated
forms of wt gp41 and wt gp41ΔCT. (A) 293 T cells were transfected
with the vector encoding wt gp41 (lane 1), and the backbone vector
pcDNA3.1(−) as a negative control (lane 2). Cells were lysed 48 hours
later, and proteins were examined by Western blot analysis. Non-
glycosylated (p35) and glycosylated (gp39-gp41) forms are marked by
arrow heads. (B) Comparative SDS-PAGE/Western blot analysis of
supernatants from 293 cells transfected with the backbone vector (lane
1), the vector expressing the wt gp41 (lane 2) and gp41 harboring a
mutation in one glycosylation site (N637T) (lane 3). (C) Comparative SDS-
PAGE/Western blot analysis of lysates from 293 T cells grown in FCS-free
medium expressing wt gp41ΔCT (lane 1), mutated gp41ΔCT(2A) (lane 2),
transfected with the backbone vector pcDNA3.1(−) (lane 3). In parallel
supernatants from non-transfected cells (lane 4), from cells transfected
with the backbone vector pcDNA3.1(−) (lane 5), from cells producing wt
gp41ΔCT (lane 6) and mutated gp41ΔCT(2A) (lane 7) were analysed. All
supernatants were concentrated 20 times, and two glycosylated forms
(about gp33 and gp36) are marked by arrow heads.
Additional file 2: Induction of IL-10 release by wt gp41 and wt
gp41ΔCT and mutations in the isu domain abrogating IL-10 release.
Cytokine release was studied in PBMCs of donor 2 after exposure to wt
gp41ΔCT, wt gp41 and gp41 with mutations 1A, 2A. The mock control
comes from the supernatant of cells transfected with the empty vector. P
values were estimated in comparison to wt gp41.
Additional file 3: Statistical significance of the IL-10 release from
PBMCs of each of the four donors (A) and of the IL-6 release from
PBMCs of donor 4 (B) as shown in Figure 3. The P values were
estimated in comparison to the wt gp41.
Additional file 4: Statistical significance of the IL-10 release (A) and
of the transcriptional activation of IL-6 (B), MMP-1 (C) and FCN1 (D)
as shown in Figure 4. P values were estimated in comparison to wt
gp41.
Additional file 5: List of the primers and probes used for real-time
PCR.
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